nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Malaise—Gemcitabine—kidney cancer	0.00132	0.00147	CcSEcCtD
Roflumilast—Hypersensitivity—Vinblastine—kidney cancer	0.00132	0.00147	CcSEcCtD
Roflumilast—Myalgia—Vincristine—kidney cancer	0.00131	0.00146	CcSEcCtD
Roflumilast—Hypersensitivity—Everolimus—kidney cancer	0.00131	0.00146	CcSEcCtD
Roflumilast—Dyspepsia—Sunitinib—kidney cancer	0.00131	0.00146	CcSEcCtD
Roflumilast—Cardiac disorder—Paclitaxel—kidney cancer	0.0013	0.00146	CcSEcCtD
Roflumilast—Weight decreased—Capecitabine—kidney cancer	0.0013	0.00145	CcSEcCtD
Roflumilast—Pneumonia—Capecitabine—kidney cancer	0.00129	0.00144	CcSEcCtD
Roflumilast—Decreased appetite—Sunitinib—kidney cancer	0.00129	0.00144	CcSEcCtD
Roflumilast—Infestation NOS—Capecitabine—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Infestation—Capecitabine—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Asthenia—Vinblastine—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Fatigue—Sunitinib—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Depression—Capecitabine—kidney cancer	0.00128	0.00143	CcSEcCtD
Roflumilast—Asthenia—Everolimus—kidney cancer	0.00128	0.00142	CcSEcCtD
Roflumilast—Constipation—Sunitinib—kidney cancer	0.00127	0.00142	CcSEcCtD
Roflumilast—Immune system disorder—Paclitaxel—kidney cancer	0.00127	0.00142	CcSEcCtD
Roflumilast—Mediastinal disorder—Paclitaxel—kidney cancer	0.00127	0.00141	CcSEcCtD
Roflumilast—Gastrointestinal pain—Sorafenib—kidney cancer	0.00126	0.00141	CcSEcCtD
Roflumilast—Infection—Vincristine—kidney cancer	0.00125	0.00139	CcSEcCtD
Roflumilast—Urinary tract infection—Capecitabine—kidney cancer	0.00125	0.00139	CcSEcCtD
Roflumilast—Myalgia—Gemcitabine—kidney cancer	0.00124	0.00139	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00123	0.00138	CcSEcCtD
Roflumilast—Nervous system disorder—Vincristine—kidney cancer	0.00123	0.00138	CcSEcCtD
Roflumilast—Asthenia—Erlotinib—kidney cancer	0.00123	0.00137	CcSEcCtD
Roflumilast—Mental disorder—Paclitaxel—kidney cancer	0.00123	0.00137	CcSEcCtD
Roflumilast—Discomfort—Gemcitabine—kidney cancer	0.00123	0.00137	CcSEcCtD
Roflumilast—Urticaria—Sorafenib—kidney cancer	0.00123	0.00137	CcSEcCtD
Roflumilast—Malnutrition—Paclitaxel—kidney cancer	0.00122	0.00137	CcSEcCtD
Roflumilast—Decreased appetite—Dactinomycin—kidney cancer	0.00122	0.00136	CcSEcCtD
Roflumilast—Diarrhoea—Vinblastine—kidney cancer	0.00122	0.00136	CcSEcCtD
Roflumilast—Abdominal pain—Sorafenib—kidney cancer	0.00122	0.00136	CcSEcCtD
Roflumilast—Diarrhoea—Everolimus—kidney cancer	0.00122	0.00136	CcSEcCtD
Roflumilast—Gastrointestinal pain—Sunitinib—kidney cancer	0.00121	0.00136	CcSEcCtD
Roflumilast—Hepatobiliary disease—Capecitabine—kidney cancer	0.00121	0.00136	CcSEcCtD
Roflumilast—Fatigue—Dactinomycin—kidney cancer	0.00121	0.00135	CcSEcCtD
Roflumilast—Tension—Paclitaxel—kidney cancer	0.0012	0.00134	CcSEcCtD
Roflumilast—Dysgeusia—Paclitaxel—kidney cancer	0.0012	0.00134	CcSEcCtD
Roflumilast—Nervousness—Paclitaxel—kidney cancer	0.00119	0.00133	CcSEcCtD
Roflumilast—Infection—Gemcitabine—kidney cancer	0.00118	0.00132	CcSEcCtD
Roflumilast—Back pain—Paclitaxel—kidney cancer	0.00118	0.00132	CcSEcCtD
Roflumilast—Dizziness—Vinblastine—kidney cancer	0.00118	0.00132	CcSEcCtD
Roflumilast—Dizziness—Everolimus—kidney cancer	0.00118	0.00131	CcSEcCtD
Roflumilast—Muscle spasms—Paclitaxel—kidney cancer	0.00118	0.00131	CcSEcCtD
Roflumilast—Abdominal pain—Sunitinib—kidney cancer	0.00117	0.00131	CcSEcCtD
Roflumilast—Diarrhoea—Erlotinib—kidney cancer	0.00117	0.00131	CcSEcCtD
Roflumilast—Nervous system disorder—Gemcitabine—kidney cancer	0.00117	0.0013	CcSEcCtD
Roflumilast—Renal failure acute—Doxorubicin—kidney cancer	0.00116	0.0013	CcSEcCtD
Roflumilast—Feeling abnormal—Dactinomycin—kidney cancer	0.00116	0.00129	CcSEcCtD
Roflumilast—Skin disorder—Gemcitabine—kidney cancer	0.00116	0.00129	CcSEcCtD
Roflumilast—Rhinitis—Capecitabine—kidney cancer	0.00116	0.00129	CcSEcCtD
Roflumilast—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00115	0.00128	CcSEcCtD
Roflumilast—Tremor—Paclitaxel—kidney cancer	0.00115	0.00128	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00114	0.00128	CcSEcCtD
Roflumilast—Hypersensitivity—Sorafenib—kidney cancer	0.00114	0.00127	CcSEcCtD
Roflumilast—Insomnia—Vincristine—kidney cancer	0.00114	0.00127	CcSEcCtD
Roflumilast—Vomiting—Vinblastine—kidney cancer	0.00114	0.00127	CcSEcCtD
Roflumilast—Dizziness—Erlotinib—kidney cancer	0.00113	0.00127	CcSEcCtD
Roflumilast—Ill-defined disorder—Paclitaxel—kidney cancer	0.00113	0.00127	CcSEcCtD
Roflumilast—Connective tissue disorder—Capecitabine—kidney cancer	0.00113	0.00126	CcSEcCtD
Roflumilast—Vomiting—Everolimus—kidney cancer	0.00113	0.00126	CcSEcCtD
Roflumilast—Rash—Everolimus—kidney cancer	0.00112	0.00125	CcSEcCtD
Roflumilast—Dermatitis—Everolimus—kidney cancer	0.00112	0.00125	CcSEcCtD
Roflumilast—Headache—Vinblastine—kidney cancer	0.00112	0.00125	CcSEcCtD
Roflumilast—Angioedema—Paclitaxel—kidney cancer	0.00112	0.00125	CcSEcCtD
Roflumilast—Headache—Everolimus—kidney cancer	0.00111	0.00124	CcSEcCtD
Roflumilast—Abdominal pain—Dactinomycin—kidney cancer	0.00111	0.00124	CcSEcCtD
Roflumilast—Asthenia—Sorafenib—kidney cancer	0.00111	0.00124	CcSEcCtD
Roflumilast—Malaise—Paclitaxel—kidney cancer	0.0011	0.00123	CcSEcCtD
Roflumilast—Vertigo—Paclitaxel—kidney cancer	0.0011	0.00123	CcSEcCtD
Roflumilast—Hypersensitivity—Sunitinib—kidney cancer	0.00109	0.00122	CcSEcCtD
Roflumilast—Decreased appetite—Vincristine—kidney cancer	0.00109	0.00122	CcSEcCtD
Roflumilast—Vomiting—Erlotinib—kidney cancer	0.00109	0.00122	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00109	0.00121	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Vincristine—kidney cancer	0.00108	0.00121	CcSEcCtD
Roflumilast—Fatigue—Vincristine—kidney cancer	0.00108	0.00121	CcSEcCtD
Roflumilast—Rash—Erlotinib—kidney cancer	0.00108	0.00121	CcSEcCtD
Roflumilast—Dermatitis—Erlotinib—kidney cancer	0.00108	0.00121	CcSEcCtD
Roflumilast—Palpitations—Paclitaxel—kidney cancer	0.00108	0.00121	CcSEcCtD
Roflumilast—Insomnia—Gemcitabine—kidney cancer	0.00108	0.0012	CcSEcCtD
Roflumilast—Headache—Erlotinib—kidney cancer	0.00108	0.0012	CcSEcCtD
Roflumilast—Constipation—Vincristine—kidney cancer	0.00107	0.0012	CcSEcCtD
Roflumilast—Cardiac disorder—Capecitabine—kidney cancer	0.00107	0.00119	CcSEcCtD
Roflumilast—Asthenia—Sunitinib—kidney cancer	0.00107	0.00119	CcSEcCtD
Roflumilast—Nausea—Vinblastine—kidney cancer	0.00106	0.00118	CcSEcCtD
Roflumilast—Nausea—Everolimus—kidney cancer	0.00106	0.00118	CcSEcCtD
Roflumilast—Diarrhoea—Sorafenib—kidney cancer	0.00106	0.00118	CcSEcCtD
Roflumilast—Immune system disorder—Capecitabine—kidney cancer	0.00104	0.00116	CcSEcCtD
Roflumilast—Myalgia—Paclitaxel—kidney cancer	0.00104	0.00116	CcSEcCtD
Roflumilast—Mediastinal disorder—Capecitabine—kidney cancer	0.00104	0.00116	CcSEcCtD
Roflumilast—Anxiety—Paclitaxel—kidney cancer	0.00104	0.00116	CcSEcCtD
Roflumilast—Decreased appetite—Gemcitabine—kidney cancer	0.00104	0.00116	CcSEcCtD
Roflumilast—Hypersensitivity—Dactinomycin—kidney cancer	0.00104	0.00116	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00103	0.00115	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00103	0.00115	CcSEcCtD
Roflumilast—Discomfort—Paclitaxel—kidney cancer	0.00103	0.00115	CcSEcCtD
Roflumilast—Fatigue—Gemcitabine—kidney cancer	0.00103	0.00115	CcSEcCtD
Roflumilast—Gastrointestinal pain—Vincristine—kidney cancer	0.00103	0.00115	CcSEcCtD
Roflumilast—Dizziness—Sorafenib—kidney cancer	0.00102	0.00114	CcSEcCtD
Roflumilast—Constipation—Gemcitabine—kidney cancer	0.00102	0.00114	CcSEcCtD
Roflumilast—Nausea—Erlotinib—kidney cancer	0.00102	0.00114	CcSEcCtD
Roflumilast—Diarrhoea—Sunitinib—kidney cancer	0.00102	0.00113	CcSEcCtD
Roflumilast—Mental disorder—Capecitabine—kidney cancer	0.00101	0.00113	CcSEcCtD
Roflumilast—Asthenia—Dactinomycin—kidney cancer	0.00101	0.00113	CcSEcCtD
Roflumilast—Malnutrition—Capecitabine—kidney cancer	0.001	0.00112	CcSEcCtD
Roflumilast—Abdominal pain—Vincristine—kidney cancer	0.000993	0.00111	CcSEcCtD
Roflumilast—Infection—Paclitaxel—kidney cancer	0.000991	0.00111	CcSEcCtD
Roflumilast—Dysgeusia—Capecitabine—kidney cancer	0.000983	0.0011	CcSEcCtD
Roflumilast—Dizziness—Sunitinib—kidney cancer	0.000982	0.0011	CcSEcCtD
Roflumilast—Feeling abnormal—Gemcitabine—kidney cancer	0.000982	0.0011	CcSEcCtD
Roflumilast—Vomiting—Sorafenib—kidney cancer	0.000982	0.0011	CcSEcCtD
Roflumilast—Nervous system disorder—Paclitaxel—kidney cancer	0.000979	0.00109	CcSEcCtD
Roflumilast—Rash—Sorafenib—kidney cancer	0.000973	0.00109	CcSEcCtD
Roflumilast—Dermatitis—Sorafenib—kidney cancer	0.000973	0.00109	CcSEcCtD
Roflumilast—Back pain—Capecitabine—kidney cancer	0.000971	0.00108	CcSEcCtD
Roflumilast—Skin disorder—Paclitaxel—kidney cancer	0.000969	0.00108	CcSEcCtD
Roflumilast—Headache—Sorafenib—kidney cancer	0.000967	0.00108	CcSEcCtD
Roflumilast—Muscle spasms—Capecitabine—kidney cancer	0.000965	0.00108	CcSEcCtD
Roflumilast—Diarrhoea—Dactinomycin—kidney cancer	0.000962	0.00107	CcSEcCtD
Roflumilast—Gastritis—Doxorubicin—kidney cancer	0.000951	0.00106	CcSEcCtD
Roflumilast—Vomiting—Sunitinib—kidney cancer	0.000945	0.00105	CcSEcCtD
Roflumilast—Tremor—Capecitabine—kidney cancer	0.00094	0.00105	CcSEcCtD
Roflumilast—Rash—Sunitinib—kidney cancer	0.000937	0.00105	CcSEcCtD
Roflumilast—Dermatitis—Sunitinib—kidney cancer	0.000936	0.00104	CcSEcCtD
Roflumilast—Ill-defined disorder—Capecitabine—kidney cancer	0.000931	0.00104	CcSEcCtD
Roflumilast—Headache—Sunitinib—kidney cancer	0.000931	0.00104	CcSEcCtD
Roflumilast—Influenza—Doxorubicin—kidney cancer	0.000928	0.00104	CcSEcCtD
Roflumilast—Hypersensitivity—Vincristine—kidney cancer	0.000926	0.00103	CcSEcCtD
Roflumilast—Nausea—Sorafenib—kidney cancer	0.000917	0.00102	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000909	0.00102	CcSEcCtD
Roflumilast—Malaise—Capecitabine—kidney cancer	0.000905	0.00101	CcSEcCtD
Roflumilast—Insomnia—Paclitaxel—kidney cancer	0.000903	0.00101	CcSEcCtD
Roflumilast—Vertigo—Capecitabine—kidney cancer	0.000902	0.00101	CcSEcCtD
Roflumilast—Asthenia—Vincristine—kidney cancer	0.000902	0.00101	CcSEcCtD
Roflumilast—Vomiting—Dactinomycin—kidney cancer	0.000894	0.000998	CcSEcCtD
Roflumilast—Palpitations—Capecitabine—kidney cancer	0.000887	0.00099	CcSEcCtD
Roflumilast—Rash—Dactinomycin—kidney cancer	0.000887	0.00099	CcSEcCtD
Roflumilast—Nausea—Sunitinib—kidney cancer	0.000882	0.000985	CcSEcCtD
Roflumilast—Dyspepsia—Paclitaxel—kidney cancer	0.000878	0.000981	CcSEcCtD
Roflumilast—Decreased appetite—Paclitaxel—kidney cancer	0.000868	0.000968	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000862	0.000962	CcSEcCtD
Roflumilast—Fatigue—Paclitaxel—kidney cancer	0.00086	0.000961	CcSEcCtD
Roflumilast—Diarrhoea—Vincristine—kidney cancer	0.00086	0.00096	CcSEcCtD
Roflumilast—Asthenia—Gemcitabine—kidney cancer	0.000855	0.000955	CcSEcCtD
Roflumilast—Myalgia—Capecitabine—kidney cancer	0.000854	0.000954	CcSEcCtD
Roflumilast—Constipation—Paclitaxel—kidney cancer	0.000853	0.000953	CcSEcCtD
Roflumilast—Anxiety—Capecitabine—kidney cancer	0.000851	0.00095	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000848	0.000947	CcSEcCtD
Roflumilast—Discomfort—Capecitabine—kidney cancer	0.000844	0.000942	CcSEcCtD
Roflumilast—Weight decreased—Doxorubicin—kidney cancer	0.00084	0.000938	CcSEcCtD
Roflumilast—Nausea—Dactinomycin—kidney cancer	0.000835	0.000933	CcSEcCtD
Roflumilast—Pneumonia—Doxorubicin—kidney cancer	0.000833	0.000929	CcSEcCtD
Roflumilast—Dizziness—Vincristine—kidney cancer	0.000831	0.000928	CcSEcCtD
Roflumilast—Infestation NOS—Doxorubicin—kidney cancer	0.000828	0.000924	CcSEcCtD
Roflumilast—Infestation—Doxorubicin—kidney cancer	0.000828	0.000924	CcSEcCtD
Roflumilast—Feeling abnormal—Paclitaxel—kidney cancer	0.000822	0.000918	CcSEcCtD
Roflumilast—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000816	0.000911	CcSEcCtD
Roflumilast—Diarrhoea—Gemcitabine—kidney cancer	0.000816	0.00091	CcSEcCtD
Roflumilast—Infection—Capecitabine—kidney cancer	0.000814	0.000908	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—kidney cancer	0.000805	0.000898	CcSEcCtD
Roflumilast—Nervous system disorder—Capecitabine—kidney cancer	0.000803	0.000897	CcSEcCtD
Roflumilast—Vomiting—Vincristine—kidney cancer	0.000799	0.000892	CcSEcCtD
Roflumilast—Skin disorder—Capecitabine—kidney cancer	0.000796	0.000888	CcSEcCtD
Roflumilast—Urticaria—Paclitaxel—kidney cancer	0.000793	0.000885	CcSEcCtD
Roflumilast—Rash—Vincristine—kidney cancer	0.000792	0.000884	CcSEcCtD
Roflumilast—Dermatitis—Vincristine—kidney cancer	0.000792	0.000884	CcSEcCtD
Roflumilast—Abdominal pain—Paclitaxel—kidney cancer	0.000789	0.000881	CcSEcCtD
Roflumilast—Headache—Vincristine—kidney cancer	0.000787	0.000879	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000783	0.000874	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—kidney cancer	0.000777	0.000867	CcSEcCtD
Roflumilast—Vomiting—Gemcitabine—kidney cancer	0.000758	0.000846	CcSEcCtD
Roflumilast—Rash—Gemcitabine—kidney cancer	0.000752	0.000839	CcSEcCtD
Roflumilast—Dermatitis—Gemcitabine—kidney cancer	0.000751	0.000838	CcSEcCtD
Roflumilast—Headache—Gemcitabine—kidney cancer	0.000747	0.000834	CcSEcCtD
Roflumilast—Nausea—Vincristine—kidney cancer	0.000746	0.000833	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000746	0.000833	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—kidney cancer	0.000745	0.000832	CcSEcCtD
Roflumilast—Insomnia—Capecitabine—kidney cancer	0.000741	0.000827	CcSEcCtD
Roflumilast—Hypersensitivity—Paclitaxel—kidney cancer	0.000735	0.000821	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—kidney cancer	0.00073	0.000815	CcSEcCtD
Roflumilast—Dyspepsia—Capecitabine—kidney cancer	0.000721	0.000805	CcSEcCtD
Roflumilast—Asthenia—Paclitaxel—kidney cancer	0.000716	0.000799	CcSEcCtD
Roflumilast—Decreased appetite—Capecitabine—kidney cancer	0.000712	0.000795	CcSEcCtD
Roflumilast—Nausea—Gemcitabine—kidney cancer	0.000708	0.00079	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000707	0.000789	CcSEcCtD
Roflumilast—Fatigue—Capecitabine—kidney cancer	0.000706	0.000788	CcSEcCtD
Roflumilast—Constipation—Capecitabine—kidney cancer	0.0007	0.000782	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—kidney cancer	0.00069	0.00077	CcSEcCtD
Roflumilast—Diarrhoea—Paclitaxel—kidney cancer	0.000683	0.000762	CcSEcCtD
Roflumilast—Feeling abnormal—Capecitabine—kidney cancer	0.000675	0.000753	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—kidney cancer	0.000671	0.000749	CcSEcCtD
Roflumilast—Gastrointestinal pain—Capecitabine—kidney cancer	0.00067	0.000748	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—kidney cancer	0.00067	0.000748	CcSEcCtD
Roflumilast—Dizziness—Paclitaxel—kidney cancer	0.00066	0.000737	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—kidney cancer	0.000651	0.000727	CcSEcCtD
Roflumilast—Urticaria—Capecitabine—kidney cancer	0.000651	0.000726	CcSEcCtD
Roflumilast—Abdominal pain—Capecitabine—kidney cancer	0.000647	0.000723	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—kidney cancer	0.000647	0.000722	CcSEcCtD
Roflumilast—Tension—Doxorubicin—kidney cancer	0.000635	0.000709	CcSEcCtD
Roflumilast—Vomiting—Paclitaxel—kidney cancer	0.000635	0.000708	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—kidney cancer	0.000633	0.000707	CcSEcCtD
Roflumilast—Rash—Paclitaxel—kidney cancer	0.000629	0.000702	CcSEcCtD
Roflumilast—Dermatitis—Paclitaxel—kidney cancer	0.000629	0.000702	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—kidney cancer	0.000628	0.000701	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—kidney cancer	0.000626	0.000698	CcSEcCtD
Roflumilast—Headache—Paclitaxel—kidney cancer	0.000625	0.000698	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—kidney cancer	0.000622	0.000694	CcSEcCtD
Roflumilast—Hypersensitivity—Capecitabine—kidney cancer	0.000603	0.000674	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—kidney cancer	0.0006	0.00067	CcSEcCtD
Roflumilast—Nausea—Paclitaxel—kidney cancer	0.000593	0.000662	CcSEcCtD
Roflumilast—Asthenia—Capecitabine—kidney cancer	0.000588	0.000656	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—kidney cancer	0.000583	0.000651	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—kidney cancer	0.000581	0.000649	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—kidney cancer	0.000572	0.000638	CcSEcCtD
Roflumilast—Diarrhoea—Capecitabine—kidney cancer	0.00056	0.000626	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—kidney cancer	0.000551	0.000615	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—kidney cancer	0.000549	0.000613	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000547	0.000611	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—kidney cancer	0.000544	0.000607	CcSEcCtD
Roflumilast—Dizziness—Capecitabine—kidney cancer	0.000542	0.000605	CcSEcCtD
Roflumilast—Infection—Doxorubicin—kidney cancer	0.000524	0.000585	CcSEcCtD
Roflumilast—Vomiting—Capecitabine—kidney cancer	0.000521	0.000581	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—kidney cancer	0.000518	0.000578	CcSEcCtD
Roflumilast—Rash—Capecitabine—kidney cancer	0.000516	0.000576	CcSEcCtD
Roflumilast—Dermatitis—Capecitabine—kidney cancer	0.000516	0.000576	CcSEcCtD
Roflumilast—Headache—Capecitabine—kidney cancer	0.000513	0.000573	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—kidney cancer	0.000513	0.000572	CcSEcCtD
Roflumilast—Nausea—Capecitabine—kidney cancer	0.000486	0.000543	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000481	0.000537	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—kidney cancer	0.000477	0.000533	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—kidney cancer	0.000465	0.000519	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—kidney cancer	0.000459	0.000512	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000456	0.000509	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—kidney cancer	0.000455	0.000508	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—kidney cancer	0.000451	0.000504	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—kidney cancer	0.000435	0.000486	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000432	0.000482	CcSEcCtD
Roflumilast—PDE4B—Opioid Signalling—MAPK1—kidney cancer	0.000424	0.00407	CbGpPWpGaD
Roflumilast—Urticaria—Doxorubicin—kidney cancer	0.000419	0.000468	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—kidney cancer	0.000417	0.000466	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—AKAP13—kidney cancer	0.000409	0.00392	CbGpPWpGaD
Roflumilast—PDE4D—G Protein Signaling Pathways—KRAS—kidney cancer	0.000407	0.00391	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—OR4C13—kidney cancer	0.000405	0.00388	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LATS1—kidney cancer	0.000391	0.00375	CbGpPWpGaD
Roflumilast—Hypersensitivity—Doxorubicin—kidney cancer	0.000389	0.000434	CcSEcCtD
Roflumilast—PDE4A—G Protein Signaling Pathways—KRAS—kidney cancer	0.000387	0.00372	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AMER1—kidney cancer	0.000382	0.00366	CbGpPWpGaD
Roflumilast—Asthenia—Doxorubicin—kidney cancer	0.000379	0.000423	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—LATS1—kidney cancer	0.000372	0.00357	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKAP13—kidney cancer	0.000371	0.00356	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—JUN—kidney cancer	0.000364	0.00349	CbGpPWpGaD
Roflumilast—Diarrhoea—Doxorubicin—kidney cancer	0.000361	0.000403	CcSEcCtD
Roflumilast—PDE4B—G Protein Signaling Pathways—KRAS—kidney cancer	0.000358	0.00344	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKAP13—kidney cancer	0.000356	0.00341	CbGpPWpGaD
Roflumilast—Dizziness—Doxorubicin—kidney cancer	0.000349	0.00039	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—ITPR2—kidney cancer	0.000347	0.00333	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LATS1—kidney cancer	0.000344	0.0033	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKAP13—kidney cancer	0.000339	0.00325	CbGpPWpGaD
Roflumilast—Vomiting—Doxorubicin—kidney cancer	0.000336	0.000375	CcSEcCtD
Roflumilast—Rash—Doxorubicin—kidney cancer	0.000333	0.000372	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—kidney cancer	0.000333	0.000371	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—AMER1—kidney cancer	0.000332	0.00319	CbGpPWpGaD
Roflumilast—Headache—Doxorubicin—kidney cancer	0.000331	0.000369	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—AKAP13—kidney cancer	0.000323	0.0031	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—JUN—kidney cancer	0.000321	0.00308	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GPC3—kidney cancer	0.00032	0.00307	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CER1—kidney cancer	0.00032	0.00307	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AMER1—kidney cancer	0.000316	0.00303	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—ITPR2—kidney cancer	0.000316	0.00303	CbGpPWpGaD
Roflumilast—Nausea—Doxorubicin—kidney cancer	0.000314	0.00035	CcSEcCtD
Roflumilast—PDE4B—GPCR downstream signaling—AKAP13—kidney cancer	0.000313	0.00301	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKAP13—kidney cancer	0.000307	0.00295	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—ITPR2—kidney cancer	0.000302	0.0029	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AMER1—kidney cancer	0.000293	0.00281	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—ANXA1—kidney cancer	0.000291	0.00279	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—ITPR2—kidney cancer	0.000288	0.00276	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKAP13—kidney cancer	0.000285	0.00273	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CER1—kidney cancer	0.000278	0.00267	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GPC3—kidney cancer	0.000278	0.00267	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—ITPR2—kidney cancer	0.000275	0.00264	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SFRP2—kidney cancer	0.000272	0.00261	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—ITPR2—kidney cancer	0.000266	0.00256	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CER1—kidney cancer	0.000265	0.00254	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GPC3—kidney cancer	0.000265	0.00254	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—ANXA1—kidney cancer	0.000264	0.00254	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—ITPR2—kidney cancer	0.000261	0.00251	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—ANXA1—kidney cancer	0.000253	0.00243	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CER1—kidney cancer	0.000245	0.00235	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GPC3—kidney cancer	0.000245	0.00235	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—ITPR2—kidney cancer	0.000242	0.00232	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—ANXA1—kidney cancer	0.000241	0.00232	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SFRP2—kidney cancer	0.000237	0.00227	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—ANXA1—kidney cancer	0.00023	0.00221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SFRP2—kidney cancer	0.000225	0.00216	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—ANXA1—kidney cancer	0.000223	0.00214	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CASP2—kidney cancer	0.000219	0.0021	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKAP13—kidney cancer	0.000219	0.0021	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—ANXA1—kidney cancer	0.000219	0.0021	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SFRP2—kidney cancer	0.000209	0.002	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—ANXA1—kidney cancer	0.000203	0.00195	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GRB7—kidney cancer	0.0002	0.00192	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKAP13—kidney cancer	0.000191	0.00183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CASP2—kidney cancer	0.000191	0.00183	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ITPR2—kidney cancer	0.000186	0.00179	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKAP13—kidney cancer	0.000182	0.00174	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CASP2—kidney cancer	0.000182	0.00174	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GRB7—kidney cancer	0.000175	0.00167	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CTNNA1—kidney cancer	0.000169	0.00162	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKAP13—kidney cancer	0.000168	0.00161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CASP2—kidney cancer	0.000168	0.00161	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HSPB1—kidney cancer	0.000168	0.00161	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EIF4EBP1—kidney cancer	0.000168	0.00161	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GRB7—kidney cancer	0.000166	0.00159	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ITPR2—kidney cancer	0.000162	0.00156	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PSMD7—kidney cancer	0.000156	0.0015	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ANXA1—kidney cancer	0.000156	0.0015	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TSC1—kidney cancer	0.000156	0.0015	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ITPR2—kidney cancer	0.000154	0.00148	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GRB7—kidney cancer	0.000154	0.00148	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FLT1—kidney cancer	0.000151	0.00145	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CTNNA1—kidney cancer	0.000147	0.00141	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EIF4EBP1—kidney cancer	0.000146	0.0014	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HSPB1—kidney cancer	0.000146	0.0014	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ITPR2—kidney cancer	0.000143	0.00137	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—POMC—kidney cancer	0.000143	0.00137	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PAK1—kidney cancer	0.00014	0.00135	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—JUNB—kidney cancer	0.00014	0.00135	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CTNNA1—kidney cancer	0.00014	0.00134	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EIF4EBP1—kidney cancer	0.000139	0.00134	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HSPB1—kidney cancer	0.000139	0.00134	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PSMD7—kidney cancer	0.000136	0.0013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TSC1—kidney cancer	0.000136	0.0013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ANXA1—kidney cancer	0.000136	0.0013	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FLT1—kidney cancer	0.000132	0.00126	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CTNNA1—kidney cancer	0.00013	0.00124	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—POMC—kidney cancer	0.00013	0.00124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PSMD7—kidney cancer	0.000129	0.00124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TSC1—kidney cancer	0.000129	0.00124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ANXA1—kidney cancer	0.000129	0.00124	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EIF4EBP1—kidney cancer	0.000129	0.00124	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HSPB1—kidney cancer	0.000129	0.00124	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FLT1—kidney cancer	0.000125	0.0012	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—POMC—kidney cancer	0.000124	0.00119	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—JUNB—kidney cancer	0.000122	0.00117	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PAK1—kidney cancer	0.000122	0.00117	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PSMD7—kidney cancer	0.00012	0.00115	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TSC1—kidney cancer	0.00012	0.00115	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ANXA1—kidney cancer	0.00012	0.00115	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—POMC—kidney cancer	0.000118	0.00113	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PAK1—kidney cancer	0.000116	0.00111	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JUNB—kidney cancer	0.000116	0.00111	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FLT1—kidney cancer	0.000116	0.00111	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF2—kidney cancer	0.000115	0.0011	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN2B—kidney cancer	0.000114	0.0011	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—POMC—kidney cancer	0.000113	0.00108	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1R—kidney cancer	0.000111	0.00106	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—POMC—kidney cancer	0.000109	0.00105	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PAK1—kidney cancer	0.000108	0.00103	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JUNB—kidney cancer	0.000108	0.00103	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—POMC—kidney cancer	0.000107	0.00103	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—RAF1—kidney cancer	0.000107	0.00102	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—IL2—kidney cancer	0.000105	0.00101	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF2—kidney cancer	9.98e-05	0.000958	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN2B—kidney cancer	9.94e-05	0.000954	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—POMC—kidney cancer	9.93e-05	0.000953	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1R—kidney cancer	9.65e-05	0.000926	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL2—kidney cancer	9.58e-05	0.000919	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF2—kidney cancer	9.5e-05	0.000912	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN2B—kidney cancer	9.46e-05	0.000908	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—RAF1—kidney cancer	9.3e-05	0.000892	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1R—kidney cancer	9.18e-05	0.000881	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—IL2—kidney cancer	9.18e-05	0.000881	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HIF1A—kidney cancer	9.13e-05	0.000876	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TSC2—kidney cancer	9.1e-05	0.000873	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—RAF1—kidney cancer	8.85e-05	0.000849	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF2—kidney cancer	8.79e-05	0.000843	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN2B—kidney cancer	8.75e-05	0.00084	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—IL2—kidney cancer	8.74e-05	0.000839	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KDR—kidney cancer	8.73e-05	0.000837	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1R—kidney cancer	8.5e-05	0.000816	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2—kidney cancer	8.34e-05	0.0008	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—RAF1—kidney cancer	8.19e-05	0.000786	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2—kidney cancer	8.09e-05	0.000776	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APC—kidney cancer	8.04e-05	0.000771	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KIT—kidney cancer	8.04e-05	0.000771	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HIF1A—kidney cancer	7.94e-05	0.000762	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2—kidney cancer	7.94e-05	0.000761	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TSC2—kidney cancer	7.92e-05	0.00076	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK3—kidney cancer	7.7e-05	0.000739	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—POMC—kidney cancer	7.65e-05	0.000734	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KDR—kidney cancer	7.6e-05	0.000729	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HIF1A—kidney cancer	7.56e-05	0.000726	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—BRAF—kidney cancer	7.56e-05	0.000725	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TSC2—kidney cancer	7.54e-05	0.000724	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2—kidney cancer	7.34e-05	0.000705	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK1—kidney cancer	7.33e-05	0.000703	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KDR—kidney cancer	7.23e-05	0.000694	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CA—kidney cancer	7e-05	0.000672	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APC—kidney cancer	7e-05	0.000672	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KIT—kidney cancer	7e-05	0.000672	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HIF1A—kidney cancer	7e-05	0.000671	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TSC2—kidney cancer	6.98e-05	0.00067	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—KRAS—kidney cancer	6.92e-05	0.000664	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK3—kidney cancer	6.7e-05	0.000643	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KDR—kidney cancer	6.69e-05	0.000642	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—POMC—kidney cancer	6.66e-05	0.000639	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APC—kidney cancer	6.66e-05	0.000639	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KIT—kidney cancer	6.66e-05	0.000639	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—BRAF—kidney cancer	6.58e-05	0.000631	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK3—kidney cancer	6.38e-05	0.000612	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK1—kidney cancer	6.38e-05	0.000612	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CA—kidney cancer	6.36e-05	0.00061	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—POMC—kidney cancer	6.34e-05	0.000608	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RAF1—kidney cancer	6.31e-05	0.000605	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RELA—kidney cancer	6.28e-05	0.000603	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—BRAF—kidney cancer	6.26e-05	0.000601	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ERBB2—kidney cancer	6.24e-05	0.000599	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KIT—kidney cancer	6.16e-05	0.000591	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APC—kidney cancer	6.16e-05	0.000591	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MTOR—kidney cancer	6.16e-05	0.000591	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CA—kidney cancer	6.09e-05	0.000585	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK1—kidney cancer	6.07e-05	0.000582	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—KRAS—kidney cancer	6.02e-05	0.000578	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK3—kidney cancer	5.9e-05	0.000566	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—POMC—kidney cancer	5.87e-05	0.000563	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CA—kidney cancer	5.8e-05	0.000557	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—BRAF—kidney cancer	5.79e-05	0.000556	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1B—kidney cancer	5.78e-05	0.000555	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—KRAS—kidney cancer	5.73e-05	0.00055	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2—kidney cancer	5.66e-05	0.000543	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK1—kidney cancer	5.62e-05	0.000539	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CA—kidney cancer	5.53e-05	0.000531	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCND1—kidney cancer	5.51e-05	0.000529	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—JUN—kidney cancer	5.5e-05	0.000528	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RAF1—kidney cancer	5.49e-05	0.000527	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RELA—kidney cancer	5.47e-05	0.000525	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CTNNB1—kidney cancer	5.46e-05	0.000524	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB2—kidney cancer	5.43e-05	0.000521	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CA—kidney cancer	5.37e-05	0.000515	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MTOR—kidney cancer	5.36e-05	0.000515	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTEN—kidney cancer	5.32e-05	0.000511	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—KRAS—kidney cancer	5.3e-05	0.000509	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CA—kidney cancer	5.27e-05	0.000505	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RAF1—kidney cancer	5.23e-05	0.000502	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RELA—kidney cancer	5.21e-05	0.000499	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB2—kidney cancer	5.17e-05	0.000496	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MTOR—kidney cancer	5.1e-05	0.00049	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1B—kidney cancer	5.03e-05	0.000483	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2—kidney cancer	4.92e-05	0.000473	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CA—kidney cancer	4.87e-05	0.000468	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RAF1—kidney cancer	4.84e-05	0.000464	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RELA—kidney cancer	4.82e-05	0.000462	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—kidney cancer	4.81e-05	0.000461	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCND1—kidney cancer	4.8e-05	0.000461	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—JUN—kidney cancer	4.79e-05	0.00046	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1B—kidney cancer	4.79e-05	0.00046	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB2—kidney cancer	4.79e-05	0.000459	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CTNNB1—kidney cancer	4.75e-05	0.000456	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MTOR—kidney cancer	4.72e-05	0.000453	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2—kidney cancer	4.69e-05	0.00045	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTEN—kidney cancer	4.63e-05	0.000445	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCND1—kidney cancer	4.57e-05	0.000439	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JUN—kidney cancer	4.56e-05	0.000438	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK3—kidney cancer	4.55e-05	0.000436	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CTNNB1—kidney cancer	4.53e-05	0.000434	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1B—kidney cancer	4.43e-05	0.000425	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—kidney cancer	4.42e-05	0.000424	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTEN—kidney cancer	4.41e-05	0.000423	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2—kidney cancer	4.34e-05	0.000416	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK1—kidney cancer	4.33e-05	0.000415	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCND1—kidney cancer	4.23e-05	0.000406	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JUN—kidney cancer	4.22e-05	0.000405	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CTNNB1—kidney cancer	4.19e-05	0.000402	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—kidney cancer	4.19e-05	0.000402	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KRAS—kidney cancer	4.09e-05	0.000392	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTEN—kidney cancer	4.08e-05	0.000392	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—kidney cancer	3.98e-05	0.000382	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK3—kidney cancer	3.96e-05	0.00038	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—kidney cancer	3.85e-05	0.00037	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK3—kidney cancer	3.77e-05	0.000362	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK1—kidney cancer	3.77e-05	0.000362	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CA—kidney cancer	3.76e-05	0.00036	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—kidney cancer	3.69e-05	0.000354	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—kidney cancer	3.67e-05	0.000352	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—kidney cancer	3.63e-05	0.000349	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK1—kidney cancer	3.59e-05	0.000344	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KRAS—kidney cancer	3.56e-05	0.000341	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK3—kidney cancer	3.49e-05	0.000335	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—kidney cancer	3.39e-05	0.000325	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KRAS—kidney cancer	3.39e-05	0.000325	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK1—kidney cancer	3.32e-05	0.000318	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CA—kidney cancer	3.27e-05	0.000314	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—kidney cancer	3.16e-05	0.000303	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KRAS—kidney cancer	3.13e-05	0.000301	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CA—kidney cancer	3.11e-05	0.000299	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—kidney cancer	3.01e-05	0.000289	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CA—kidney cancer	2.88e-05	0.000276	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—kidney cancer	2.79e-05	0.000267	CbGpPWpGaD
